Access Pharmaceuticals is an emerging pharmaceutical company that develops polymer-linked cytotoxics for use in the treatment of cancer. Its lead product, AP5346, is in Phase 2 clinical testing. The Company also has other advanced drug delivery technologies, including vitamin-mediated targeted delivery, nonparticle aggregates and oral drug delivery products. Access Pharmaceuticals has headquarters in Dallas and is traded publicly on the American Stock Exchange under the symbol ACCP.